Meglumine gamma linolenate

Drug Profile

Meglumine gamma linolenate

Alternative Names: Megla; Meglumine gamma linolenic acid; Meglumine GLA; SC 101i

Latest Information Update: 22 Jan 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scotia Pharmaceuticals [CEASED]
  • Class Antineoplastics; Hexosamines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bladder cancer

Most Recent Events

  • 22 Jan 2002 Discontinued-II for Bladder cancer in United Kingdom (Intratumoural)
  • 19 Oct 2000 Phase-II clinical trials for Bladder cancer in United Kingdom (Intratumoural)
  • 19 Oct 2000 A clinical study in patients with bladder cancer has been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top